tiprankstipranks
Seres Therapeutics (DE:1S9)
BERLIN:1S9

Seres Therapeutics (1S9) Income Statement

1 Followers

Seres Therapeutics Income Statement

Last quarter (Q4 2023), Seres Therapeutics's total revenue was $64.00K, a decrease of -93.44% from the same quarter last year. In Q4, Seres Therapeutics's net income was $-41.25M. See Seres Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 126.33M$ 126.33M$ 7.13M$ 143.86M$ 33.22M$ 34.51M
Cost of Revenue
------
Gross Profit
$ 126.33M$ 126.33M$ 7.13M$ 144.93M--
Operating Expense
$ 234.31M$ 234.31M$ 253.62M$ -209.42M$ 121.34M$ 104.89M
Operating Income
$ -103.77M$ -107.98M$ -246.49M$ -64.49M$ -88.13M$ -70.38M
Net Non Operating Interest Income Expense
$ -5.88M$ -5.88M$ -2.96M$ -40.00K$ -1.98M$ 531.00K
Other Income Expense
$ -134.00K$ -134.00K$ 705.00K$ 1.04M$ 981.00K$ -426.00K
Pretax Income
$ -119.53M$ -112.32M$ -248.15M$ -65.58M$ -89.13M$ -70.28M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -114.76M$ -112.32M$ -248.15M$ -65.58M$ -89.13M$ -70.28M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 146.15M$ 234.31M$ 253.62M$ -209.42M$ 121.34M$ 104.89M
Net Income From Continuing And Discontinued Operation
$ -113.72M$ -113.72M$ -250.16M$ -65.58M$ -89.13M$ -70.28M
Normalized Income
$ -38.62M-$ -196.04M-$ -89.13M$ -68.79M
Interest Expense
----$ 2.92M$ 502.00K
EBIT
$ -61.19M$ -99.14M$ -242.13M$ -65.54M$ -86.20M$ -69.78M
EBITDA
$ -56.08M$ -91.99M$ -234.11M$ -56.57M$ -79.63M$ -62.17M
Currency in USD

Seres Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis